logo

Repros Therapeutics Inc. (RPRX)



Trade RPRX now with
  Date
  Headline
8/14/2017 9:25:48 AM Repros Therapeutics Q2 Net Loss $2.2 Mln Or $0.08/shr Vs. Net Loss Of $4.3 Million Or $0.18/shr Prior Year
4/10/2017 9:34:47 AM Repros Therapeutics Trading Halted ; Expected To Resume At 9:50 AM ET
4/10/2017 9:20:24 AM Repros Therapeutics Names Larry Dillaha President And CEO, Effective Immediately
4/10/2017 9:17:54 AM Repros Therapeutics : FDA Confirms Proellex To Continue On Current Partial Clinical Hold
3/31/2017 9:18:06 AM Repros Therapeutics Q4 Loss $4.0 Mln Or $0.16/shr Vs Loss $6.3 Mln Or $0.26/shr Prior Year
2/2/2017 9:23:16 AM Repros Therapeutics President And CEO Joseph Podolski Is Leaving; Larry Dillaha Named President And CEO On Interim Basis
1/30/2017 9:17:30 AM Repros: FDA Grants End Of Phase 2 Meeting On Phase 3 Requirements For Oral Proellex In Treatment Of Uterine Fibroids
12/6/2016 8:04:24 PM Repros : FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism
11/8/2016 4:06:08 PM Repros Therapeutics Q3 Loss/share $0.17 Vs. Loss $0.27 Year Ago
10/5/2016 10:39:00 AM Repros Reports Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
9/26/2016 9:23:20 AM FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
8/9/2016 9:17:36 AM Repros Therapeutics Q2 Loss $4.3 Mln Or $0.18/shr Vs. Loss $7.8 Mln Or $0.32/shr Prior Year